A subset of patients treated with selective TRK inhibitors (including the newly approved larotrectinib) develop off-target resistance mediated by genomic acquisition of MAPK pathway-activating alterations, and may benefit from combined targeted therapy.
- Emiliano Cocco
- Alison M. Schram
- Maurizio Scaltriti
